Bruker Daltonics NBC Business Receives Frost & Sullivan Product Innovation Award for Chemical and Biological Agent Detectors.

BILLERICA, Mass. -- Bruker BioSciences Corporation (NASDAQ: BRKR) today announces that Frost & Sullivan has selected the Company's Bruker Daltonics subsidiary for their 2004 Product Innovation Award in the Chemical & Biological Agent Detector Markets.

Frost & Sullivan Industry Analyst Matthew Farr stated: "Bruker Daltonics has more than two decades of Nuclear, Biological and Chemical (NBC) detection experience. This experience has led Bruker Daltonics to develop a broad range of NBC detection products based on several technology platforms."

Bruker Daltonics' NBC product line includes a nuclear radiation detector, the hand-held SVG-2, which can be vehicle mounted. The SVG-2 incorporates sensors for detecting gamma and neutron radiation. Bruker Daltonics also produces two complementary biological agent detectors: the Chemical Biological Mass Spectrometer (CBMS) can detect and classify biological agents in as little as three minutes without operator intervention. The CBMS is used in the US Army's Biological Integrated Detections System. The new APSIS(TM) is a fieldable DNA microarray system for the subsequent identification of harmful pathogens.

In addition, Bruker Daltonics has a wide range of chemical agent detectors: the HAWK(TM) is a long distance chemical detector for defense and homeland security. It is based on infrared technology and has the ability to scan the horizon automatically. It can remotely identify most known chemical agents, as well as important toxic industrial chemicals, over distances up to three miles. A new introduction is the Mobile Mass Spectrometer (MM2) for NATO reconnaissance vehicles. The MM2(TM) is ruggedized, fully automatic and weighs just 30 kg. Finally, Bruker Daltonics offers a family of small Rapid Alarm and Identification Devices (RAID) for chemical agents based on ion mobility technology. The RAID(TM) instruments can be configured as hand-held, portable or mounted point detectors with automatic alarm functions for the field, vehicles/ships or for buildings.

Frost & Sullivan President Krishna Srinivasan explained: "Bruker Daltonics has expanded the range of products it offers by using new and innovative technologies. Developing these new technologies requires a firm commitment to excellence; Bruker Daltonics has obviously made this commitment to future growth and technological advancement."

Frank Laukien, Ph.D., President and CEO of Bruker Daltonics, commented: "We are gratified by this award, and very pleased to have been recognized by Frost & Sullivan for the fifth time now in three years for our best practices in product line innovation and growth strategy. We expect our NBC product line to continue to make important contributions in U.S. and NATO defense and homeland security applications."

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.